Home > Gastroenterology > CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab

CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab

Presented by
Prof. Ian Chau, Royal Marsden Hospital, UK
Conference
ASCO GI 2024
Trial
Phase 3, CheckMate 648
Doi
https://doi.org/10.55788/5ec6a468
Participants with advanced oesophageal squamous cell carcinoma (OSCC) who were treated with nivolumab plus chemotherapy or with nivolumab plus ipilimumab had clinically meaningful prolonged overall survival times without symptoms or toxicity compared with participants who were treated with chemotherapy alone, revealed an analysis into the data of the CheckMate 648 trial.

Nivolumab plus chemotherapy and nivolumab plus ipilimumab have been approved as first-line therapies for patients with advanced OSCC based on the results of the phase 3 CheckMate 648 trial (n=970) [1]. At ASCO-GI, Prof. Ian Chau (Royal Marsden Hospital, UK) presented the results of a quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis to compare the quality and quantity of survival of participants who received either one of the two nivolumab-containing regimens with patients who received chemotherapy alone [2].

Participants in the nivolumab plus chemotherapy arm spent the most time in survival without symptoms or toxicity (8.0 months). In the nivolumab plus ipilimumab arm and chemotherapy alone arm the corresponding durations were 6.6 months and 5.8 months, respectively. Participants in the nivolumab-containing arms also spent more survival time in toxicity or with symptoms.

Prof. Chau shared that the difference in Q-TWiST duration between the nivolumab plus chemotherapy arm and chemotherapy alone arm was 1.7 months, exceeding the threshold for clinical importance of 1.1 months. Similarly, the Q-TWiST difference between nivolumab plus ipilimumab and chemotherapy alone was 1.3 months, in favour of the first regimen.

“The Q-TWiST analysis favoured nivolumab plus chemotherapy and nivolumab plus ipilimumab over chemotherapy alone, further supporting these regimens as first-line treatment options for patients with advanced OSCC,” concluded Prof. Chau.

  1. Doki Y, et al. N Engl J Med 2022;386:449-462.
  2. Chau I, et al. A quality-adjusted time without symptoms and toxicity analysis comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy in patients with advanced esophageal squamous cell carcinoma: CheckMate 648. Abstract 251, ASCO Gastrointestinal Cancers Symposium 2024, 18–20 January, San Francisco, CA, USA.

Copyright ©2024 Medicom Medical Publishers



Posted on